Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases
Status:
Recruiting
Trial end date:
2025-06-01
Target enrollment:
Participant gender:
Summary
To evaluate the safety, efficacy and tolerability of sparsentan oral suspension and assess
changes in proteinuria after once-daily dosing over the 108-week treatment period.